---
title: "CISEN: SSY GROUP completed the reduction of 4.52 million shares, with its shareholding decreasing to 5.11%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258649534.md"
description: "CISEN announced that its shareholder, Shijiazhuang Four Pharmaceutical Co., Ltd., which holds more than 5% of the shares, has completed its reduction plan, selling 4.52 million shares, reducing its shareholding ratio to 5.11%. Before the reduction, Shijiazhuang Four Pharmaceutical held 27.66 million unrestricted tradable shares, accounting for 6.11% of the total share capital. The reduction price range was between 19.70 - 21.17 yuan/share, with a total amount of 91.22564 million yuan"
datetime: "2025-09-24T08:05:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258649534.md)
  - [en](https://longbridge.com/en/news/258649534.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258649534.md)
generator: "portal-rs"
---

# CISEN: SSY GROUP completed the reduction of 4.52 million shares, with its shareholding decreasing to 5.11%

CISEN announced that its shareholder, Shijiazhuang Four Pharmaceutical Co., Ltd., which holds more than 5% of the shares, has completed its reduction plan. Before this reduction, Shijiazhuang Four Pharmaceutical held 27,661,441 unrestricted tradable shares, accounting for 6.11% of the total share capital. On August 30, 2025, it disclosed the reduction plan, intending to reduce no more than 4,527,000 shares through centralized bidding. As of September 24, Shijiazhuang Four Pharmaceutical had cumulatively reduced 4,520,000 shares, accounting for 0.998% of the total share capital, with a reduction price range of 19.70 - 21.17 yuan/share, totaling 91,220,564 yuan. After the reduction, Shijiazhuang Four Pharmaceutical's holdings decreased to 23,141,441 shares, with a holding ratio of 5.11%. This reduction is consistent with the plan and has not been terminated early

### Related Stocks

- [603367.CN](https://longbridge.com/en/quote/603367.CN.md)
- [02005.HK](https://longbridge.com/en/quote/02005.HK.md)

## Related News & Research

- [SSY Group wins China NMPA approval for vitamin K1 injection product](https://longbridge.com/en/news/296431792.md)
- [Tai Hing Group Holdings (SEHK:6811) Stock Price Tracks Profit Rebound Against Thin Margins](https://longbridge.com/en/news/296688951.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [China Petroleum & Chemical reports 1H results; gives full- year outlook](https://longbridge.com/en/news/296744690.md)
- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**